08 October, 2017
Hightower Advisors Llc who had been investing in Omnicom Group Inc for a number of months, seems to be bullish on the $17.37B market cap company. As of the end of the quarter Ironbridge Capital Management Lp had acquired a total of 15,230 shares growing its position 49.4%. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post ($7.14) earnings per share for the current year.
About 30,875 shares traded. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 6.49% since October 5, 2016 and is downtrending. It has outperformed by 17.67% the S&P500. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.16 on Accern's scale. Ultragenyx Pharmaceutical Inc had 47 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has "Buy" rating by Canaccord Genuity given on Friday, July 28. The value of the investment in RARE decreased from $10,828,000 to $9,969,000 decreasing 7.9% for the reporting period. Finally, Stifel Nicolaus reiterated a "buy" rating and issued a $85.00 price objective (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd.
In other news, CEO Emil D. Kakkis bought 7,500 shares of the stock in a transaction dated Monday, August 28th. On Friday, February 19 the stock rating was initiated by Leerink Swann with "Outperform". Robert W. Baird reiterated an "outperform" rating and issued a $90.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 19th. During the same quarter in the previous year, the firm earned ($1.46) EPS. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping analysts' consensus estimates of ($1.73) by $0.01.
Investors sentiment increased to 1.84 in 2017 Q2. Its up 0.75, from 1.09 in 2017Q1. It improved, as 41 investors sold CBOE shares while 79 reduced holdings. 73 funds opened positions while 136 raised stakes. Aviva Public Limited Co holds 0.2% or 434,873 shares in its portfolio. Invesco Limited, Georgia-based fund reported 261,584 shares. Cibc Asset Mgmt Inc reported 8,173 shares. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company's stock worth $194,421,000 after acquiring an additional 135,335 shares during the last quarter. (NASDAQ:RARE) traded up 0.804% on Thursday, hitting $57.045. Moreover, Bp Plc has 0.07% invested in Morneau Shepell Inc (TSE:MSI). Usa Fincl Portformulas accumulated 11,528 shares. Institutional investors own 96.35% of the company's stock. Amalgamated Bank reported 22,130 shares or 0.07% of all its holdings. Cwm holds 0% or 3 shares. Beutel Goodman &, Ontario - Canada-based fund reported 2.40 million shares. Td Asset Mgmt, Ontario - Canada-based fund reported 396,635 shares.
Among 20 analysts covering CBOE Holdings Inc (NASDAQ:CBOE), 9 have Buy rating, 2 Sell and 9 Hold.
August 23 investment analysts at JMP Securities left the company rating at "Market Outperform" but lowered the price target to $80.00 from $84.00. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. The stock has "Underperform" rating by Bank of America on Thursday, August 11. (NASDAQ:RARE) by 4.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The stock decreased 1.38% or $0.78 during the last trading session, reaching $55.81. On Friday, January 13 the stock rating was upgraded by Credit Suisse to "Outperform". The shares were sold at an average price of $86.34, for a total transaction of $215,850.00. It also upped Party City Holdco Inc stake by 70,232 shares and now owns 103,860 shares.
Since May 12, 2017, it had 0 buys, and 5 sales for $35.98 million activity. RATTERMAN JOSEPH P had sold 175,955 shares worth $14.79M.
Investors sentiment increased to 1.84 in Q2 2017. Its up 0.75, from 1.09 in 2017Q1.
Traders are feeling more bearish on Ultragenyx Pharmaceutical Inc.as evidenced by the rise in short interest. 19 funds opened positions while 71 raised stakes. Ahl Prtn Llp holds 45,399 shares.
Point72 Asset Management, L.p. cut its stake by selling 15,000 shares a decrease of 18.8%. Citadel Advsrs Ltd Liability Com holds 0.01% or 124,231 shares in its portfolio. Clearbridge Limited Liability holds 1,097 shares. Cap Ww Invsts stated it has 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Jennison Associate Ltd Limited Liability Company owns 470,032 shares or 0.03% of their U.S. portfolio. California State Teachers Retirement System reported 70,106 shares. BMO Capital Markets maintained the shares of OMC in report on Thursday, July 13 with "Hold" rating. Rhenman & Partners Asset Management Ab augmented its holdings by buying 25,573 shares an increase of 255.7% in the quarter. 5,570 were accumulated by Cubist Systematic Strategies Lc. Morgan Stanley invested in 66,621 shares or 0% of the stock. Reynders Mcveigh Mngmt Limited Com accumulated 14,083 shares.
About 141,785 shares traded. BidaskClub raised Ultragenyx Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Tuesday, July 25th. It has underperformed by 23.19% the S&P500. The company was maintained on Monday, October 2 by Robert W. Baird. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It now has negative earnings.
